Viking Therapeutics, Inc. 8-K

What Happened
Viking Therapeutics, Inc. (VKTX) filed a Form 8‑K on April 29, 2026 (Item 2.02) to announce and furnish a press release reporting its financial results for the quarter ended March 31, 2026 and providing a corporate update. The press release is furnished as Exhibit 99.1 to the Form 8‑K. The filing was signed by President and CEO Brian Lian, Ph.D.

Key Details

• Filing date: April 29, 2026; reporting period: quarter ended March 31, 2026.
• Item reported: 2.02 — Results of Operations and Financial Condition (press release furnished as Exhibit 99.1).
• Exhibit: 99.1 contains the full press release; the Form 8‑K also includes Inline XBRL cover page data (Exhibit 104).
• Signed by CEO Brian Lian, Ph.D., as the company’s principal executive officer.

Why It Matters
This filing provides Viking’s latest quarterly results and corporate update, which are material for investors tracking the company’s earnings, revenue trends, cash position, and business progress. Retail investors should read the furnished press release (Exhibit 99.1) and the company’s subsequent filings for the full financial figures and any operational guidance or program updates that could affect the stock.